OncoMatch/Clinical Trials/NCT07701486
A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Is NCT07701486 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) and Nab-paclitaxel + Gemcitabine for pancreas cancer, metastatic.
Treatment: VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) · Nab-paclitaxel + Gemcitabine — The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer. Participants will receive three planned doses of VCN-01, given once every 56 days. Each dose of VCN-01 is followed one week later by two cycles of standard chemotherapy with gemcitabine and nab-paclitaxel. Participants will be monitored throughout the study for safety and side effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1 at enrollment
Prior therapy
Cannot have received: surgery for metastatic pancreatic cancer
Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that: Palliative radiotherapy for pain is permitted; Placement of a biliary stent/tube is permitted.
Cannot have received: radiotherapy for metastatic pancreatic cancer
Exception: palliative radiotherapy for pain is permitted
Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that: Palliative radiotherapy for pain is permitted; Placement of a biliary stent/tube is permitted.
Cannot have received: chemotherapy for metastatic pancreatic cancer
Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that: Palliative radiotherapy for pain is permitted; Placement of a biliary stent/tube is permitted.
Cannot have received: investigational therapy for metastatic pancreatic cancer
Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that: Palliative radiotherapy for pain is permitted; Placement of a biliary stent/tube is permitted.
Lab requirements
Blood counts
Leukocytes ≥3.0x10^3/mcL; ANC ≥1.5x10^9/L; Hemoglobin ≥9 g/dL; Platelets ≥100x10^9/L
Kidney function
Serum creatinine ≤1.5xULN; or, if serum creatinine >1.5xULN, estimated creatinine clearance >50 mL/min (Cockcroft and Gault)
Liver function
Total bilirubin ≤1.5xULN; ALT and AST ≤2.5xULN (<5xULN if liver metastases present)
Cardiac function
LVEF ≥50% by ECHO or MUGA; QTcF ≤450 ms (men) or ≤470 ms (women)
Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment: ... Adequate left ventricular ejection fraction (LVEF) ≥ 50% measured by ECHO or MUGA and QT interval corrected by Fridericia (QTcF) assessment ≤ 450 ms for men or ≤ 470 ms for women.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07701486 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery for metastatic pancreatic cancer, radiotherapy for metastatic pancreatic cancer, chemotherapy for metastatic pancreatic cancer disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages